UAB

Prevent Blindness Issues Call for Nominations for the 2023 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award

Retrieved on: 
Wednesday, January 4, 2023
Eye, School, University, Massachusetts Eye and Ear, Public health, Head, Research, UAB, Ohio Department of Health, Master of Science, FACS, OD, United States Department of Veterans Affairs, Research to Prevent Blindness, New England College, University of Illinois Urbana-Champaign, Veterans' affairs, Visual Science, Illinois Eye and Ear Infirmary, DPA, University college, Visual impairment, MBA, Doctor of Philosophy, Professor, Policy, Ear, Johns Hopkins University, Severe cognitive impairment, Essay, New England College of Optometry, ROP, University of Alabama, Bascom Palmer Eye Institute, UIC, New England, Pharmaceutical industry, Management, Optometry, Ophthalmology, MD, Child, MPH

CHICAGO, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's oldest volunteer eye health and safety organization, is issuing the call for nominations for the "2023 Jenny Pomeroy Award for Excellence in Vision and Public Health," and the fourth annual "Rising Visionary Award." Both awards will be formally presented at the 12th Annual Prevent Blindness Focus on Eye Health National Summit, on July 12-13, 2023.

Key Points: 
  • Both awards will be formally presented at the 12th Annual Prevent Blindness Focus on Eye Health National Summit, on July 12-13, 2023.
  • The highest honor that Prevent Blindness bestows, the award is a tribute to Jenny Pomeroy, who was the CEO of Prevent Blindness Georgia from 1996 until 2013, and an accomplished leader in advancing public health and policy for vision and eye health issues.
  • The recipient of the 2022 Jenny Pomeroy Award for Excellence in Vision and Public Health was VOSH/International, a volunteer-based organization.
  • For more information on the Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, please visit https://preventblindness.org/jenny-pomeroy-award-for-excellence-in-visio... .

AI Metrics Research Received "Best of AJR" Award by the American Journal of Roentgenology

Retrieved on: 
Monday, December 19, 2022
American Journal of Roentgenology, Metric, Fasting, Patient, Chronic liver disease, MRI, Decompensation, AJR, Mayo Clinic, Duke University, Radiology, University, Cirrhosis, Cleveland Clinic, University of Wisconsin–Madison, CT, Hepatitis C, UC, LSN, University of California, San Diego, Oncology, Gastrointestinal tract, American Journal, Software, Research, UAB, Hospital, Biomarker, Medical imaging

BIRMINGHAM, Ala., Dec. 19, 2022 /PRNewswire-PRWeb/ -- AI Metrics, an early stage radiology software company, announced that the company's recently published research in the American Journal of Roentgenology (AJR) has been awarded the Best of AJR in the Gastrointestinal Imaging section for 2022.

Key Points: 
  • BIRMINGHAM, Ala., Dec. 19, 2022 /PRNewswire-PRWeb/ -- AI Metrics, an early stage radiology software company, announced that the company's recently published research in the American Journal of Roentgenology (AJR) has been awarded the Best of AJR in the Gastrointestinal Imaging section for 2022.
  • AI Metrics commercialized Dr. Smith's research by developing a software module that enables patient evaluation from standard CT scans.
  • "LSN dramatically reduces the equipment costs for hospitals," said Bob Jacobus, CEO, AI Metrics.
  • The company holds 20 U.S. and international patents, and its technology is currently in use at 10 healthcare institutions globally.

GlobalBlock Reports AGM Voting Results and Grant of Stock Options

Retrieved on: 
Wednesday, December 7, 2022
Blockchain.com, UAB, OTC Markets Group, FSE, Remuneration, TSX, The Meeting, Meeting, Security (finance)

A total of 53,154,500 common shares, or 50.65% of the issued and outstanding common shares of the Company were represented at the Meeting.

Key Points: 
  • A total of 53,154,500 common shares, or 50.65% of the issued and outstanding common shares of the Company were represented at the Meeting.
  • The Company also announces the grant of incentive stock options to acquire a total of 100,000 common shares of the Company at an exercise price of $0.25 per share, with such options to vest one-half on the first anniversary of the date of grant and the remaining one-half on the second anniversary of the date of grant.
  • The options expire five (5) years from the date of grant.
  • Currently, GlobalBlock Europe only accepts United Kingdom and Lithuania resident clients or customers, and certain clients or customers that initiate contact with GlobalBlock Europe, for its digital asset broker or trading services.

SPOC Automation Welcomes Kaila Szmajda as Global Demand Planner

Retrieved on: 
Tuesday, December 13, 2022
SPOC, Auburn University, Auburn University College of Architecture, Design, and Construction, AL, UAB, Automation, Love, Economics, Root cause analysis, University, Education, Engineering, A Call for Unity, Marketing, Forecasting, MBA, Management, Retail

TRUSSVILLE, Ala., Dec. 13, 2022 /PRNewswire/ -- SPOC is pleased to welcome Kaila Szmajda to the team in her new role as Global Demand Planner. She joins SPOC after having graduated from Auburn University's MBA program.

Key Points: 
  • SPOC Automation announces new hire, Kaila Szmajda, who will join the team as Global Demand Planner.
  • TRUSSVILLE, Ala., Dec. 13, 2022 /PRNewswire/ -- SPOC is pleased to welcome Kaila Szmajda to the team in her new role as Global Demand Planner.
  • During the summer of 2022, she interned with SPOC, working in global demand planning.
  • As a global demand planner, Szmajda will also lead meetings with sales and service teams, product management, engineering, and procurement to ensure that customer demand signals, new product introductions, and other market trends are anticipated.

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.

Retrieved on: 
Wednesday, December 7, 2022
Therapy, Neurodegeneration, AAV, Waste, OTC, Chromosome, Alzheimer's disease, Amyotrophic lateral sclerosis, UAB, Protein, Metabolism, Patient, DNA, Cancer, Heart failure, Mammal, Research, Longevity, Disease, Degenerative disease, ALS, Drug development, Cell nucleus, COVID-19, Cell, Human, Ageing, LEAS, Statement, Clotho, Parkinson's disease, RNA, Chronic kidney disease, Pharmaceutical industry, Vaccine

The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).

Key Points: 
  • The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).
  • Our Klotho gene therapy is a unique approach to treating ALS.
  • The therapeutic results generated in experimental animal models of ALS offers great promise for patients afflicted with the disease.
  • Other neurodegenerative diseases will utilize a tissue-specific promoter, a secreted-Klotho gene variant called s-KL, and adeno-associated virus (AAV) or lipid particles to deliver the gene inside a patient's cells.

UAB Cardiogenomics Clinic and Allelica to perform polygenic risk score clinical implementation study

Retrieved on: 
Tuesday, November 29, 2022
Birmingham, Translation, Radar, Genetics, Fortis Healthcare, CAD, University, Multimedia, Risk, Clinic, Genetic counseling, Degenerative disease, Physician, Learning, Cardiovascular disease, Education, Patient, Risk assessment, CLIA, Death, Disease, Standard of care, Precision medicine, A Call for Unity, Risk management, PRS, Infarction, Coronary artery disease, CAP, UAB, Algorithm, Medical device

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease. The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.

Key Points: 
  • The Cardiogenomics Clinic at the University of Alabama at Birmingham and Allelica are partnering to perform a clinical implementation study to assess how polygenic risk score integration changes clinical management and health outcomes in a US health system.
  • NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease.
  • The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.
  • The results of this study will help to establish a clear pathway for providers for the clinical implementation of PRS in cardiovascular disease risk management and prevention.

GlobalBlock Provides Reassurance Amid Market Volatility

Retrieved on: 
Thursday, November 17, 2022
UAB, OTC Markets Group, FTX, FCA, FSE, Financial services

London, United Kingdom and Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - GlobalBlock Digital Asset Trading Limited (TSXV: BLOK) (OTC Pink: BLVDF) (FSE: BD4) (the "Company" or "GlobalBlock"), wishes to reassure investors and customers that its service led digital asset broker GlobalBlock Europe, UAB, an operating subsidiary of the Company, has no exposure to FTX or any of its affiliated businesses.

Key Points: 
  • GlobalBlock has robust security and custody measures in place to ensure clients' funds are protected.
  • GlobalBlock has never deployed any client funds in any way other than directed by its clients.
  • Our focus on customer service provides our clients with reassurance that an expert is always just a telephone call away.
  • GlobalBlock Digital Asset Trading Limited is a publicly traded holding company (TSXV: BLOK) whose wholly-owned operating subsidiary, GlobalBlock Europe, UAB ( https://www.globalblock.eu ), is a European Union based digital asset broker that provides a personalised telephone brokerage service, trading platform and mobile app.

CRAG and IRTA Expand Their International Partnership With Front Range Biosciences to Address the Growing Threat of Hop Latent Viroid Disease in Cannabis

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Center of excellence, Seed, Molecular biology, Food, Center, Ministry, Autonomous university, Partnership, Research, UAB, Spanish National Research Council, Adoption, Organization, Environment, Plant, Population, CERCA, CSIC, Innovation, AEMPS, Efficiency, Genetics, Institute, MAS, UB, Government, University of Barcelona, FRB, Spanish Agency of Medicines and Medical Devices, Shimadzu, Breeding, Union, President of the Government of Catalonia, Autonomous University of Barcelona, IRTA, Medical device, DACC, Cannabis, University, Agriculture, Animal, CEO, Industry, Chemistry, Aquaculture, Drug, Science, Technology, Medicine, Health

These techniques add to the suite of already existing licensed technologies, including phytochemical quantification and molecular marker analysis, for commercial use to the CRAG and IRTA.

Key Points: 
  • These techniques add to the suite of already existing licensed technologies, including phytochemical quantification and molecular marker analysis, for commercial use to the CRAG and IRTA.
  • "CRAG is a world-class research center, and we are pleased to extend our partnership with them by introducing technologies and services that will transform cannabis markets across Europe," says Chris Driessen, CEO of FRB.
  • Spain was one of the first European countries to decriminalize the personal use and cultivation of cannabis for self-consumption.
  • Since 2016, CRAG is recognized as a "Severo Ochoa Centre of Excellence" by the Spanish Ministry of Science and Innovation.